Human Senescence Atlas Turns Aging Into a Mapping Problem
NIH's SenNet atlas does not prove an anti-aging therapy. It gives longevity science a harder measurement layer.
Read the briefing →Force 10 / Health
Health is where frontier claims meet human stakes.
This hub tracks how AI, biotech, and longevity science collide with evidence, care delivery, diagnostics, prevention, and the lived reality of medicine.
Evidence
Care
Outcomes
Current signal
Latest ↓
Read now
Latest Health signals.
Newest health stories on proof, care delivery, and human outcomes.
ER-100 First Human Dosed: The Rejuvenation Test Has Left the Lab
The first human dosing of ER-100 does not prove age reversal. It starts the evidence clock for one of longevity's boldest ideas.
Hepcludex FDA Approval: What Bulevirtide Changes for Chronic Hepatitis D
FDA approval gives chronic hepatitis D a US treatment pathway. The harder question is whether evidence, diagnosis, price and payer access can catch up.
Global Cancer Workforce Crisis: Why Better Treatments Still Need a Capacity Stack
A Lancet Oncology Commission turns cancer care into an infrastructure story: survival depends on people, diagnostics, equipment, and capacity.
Semaglutide Failed in Alzheimer's. The Bigger Lesson Is About Evidence.
Two major Alzheimer's trials showed semaglutide did not slow clinical decline. The result is a hard lesson in what evidence can and cannot prove.
Rapamycin Still Needs Human Proof
Rapamycin has real longevity science behind it. That does not make it a proven anti-aging drug for healthy humans.
Partial Epigenetic Reprogramming Human Trial: Longevity’s Reality Check
ER-100 is a narrow eye-disease trial, but it may be the first real test of whether cellular rejuvenation can survive clinical evidence.
Field note
Read the board before it turns into noise.
A compact operating note for Health: what changed, what to watch, what to doubt, and where the constraint sits.
Measurement moves upstream
Better diagnostics and biomarkers could change what medicine sees before symptoms dominate.
Validated diagnostics
Tools that improve decisions and outcomes in real care settings.
A model result equals better care.
A biomarker is the same as an outcome.
Clinical validation
A promising signal must become evidence that changes outcomes.
Corridors
Routes around Health.
Use these routes when a story crosses into neighboring fields, forces, or reading formats.
Latest corridor story
Human Senescence Atlas Turns Aging Into a Mapping Problem
Latest corridor story
Hepcludex FDA Approval: What Bulevirtide Changes for Chronic Hepatitis D
Archive
All Health stories, compact.
Use the archive for retrieval; the map above carries the orientation.
ER-100 First Human Dosed: The Rejuvenation Test Has Left the Lab
The first human dosing of ER-100 does not prove age reversal. It starts the evidence clock for one of longevity's boldest ideas.
Hepcludex FDA Approval: What Bulevirtide Changes for Chronic Hepatitis D
FDA approval gives chronic hepatitis D a US treatment pathway. The harder question is whether evidence, diagnosis, price and payer access can catch up.
Global Cancer Workforce Crisis: Why Better Treatments Still Need a Capacity Stack
A Lancet Oncology Commission turns cancer care into an infrastructure story: survival depends on people, diagnostics, equipment, and capacity.
Semaglutide Failed in Alzheimer's. The Bigger Lesson Is About Evidence.
Two major Alzheimer's trials showed semaglutide did not slow clinical decline. The result is a hard lesson in what evidence can and cannot prove.
Rapamycin Still Needs Human Proof
Rapamycin has real longevity science behind it. That does not make it a proven anti-aging drug for healthy humans.
Partial Epigenetic Reprogramming Human Trial: Longevity’s Reality Check
ER-100 is a narrow eye-disease trial, but it may be the first real test of whether cellular rejuvenation can survive clinical evidence.
The First Human Rejuvenation Trial: What ER-100 Really Changes
ER-100 matters because rejuvenation language is finally being forced to answer to medicine.
Prime Editing in Humans: First Proof, Big Questions Ahead
Prime editing has crossed from elegant theory into the clinic, but the hardest questions are still ahead.
Personalized Gene Editing for One Baby Is a Breakthrough—And a Stress Test for Medicine
A baby’s personalized CRISPR treatment shows what precision medicine can become. It also exposes the manufacturing, regulatory, and access problems medicine has not solved yet.